Thrivent Financial for Lutherans Boosts Stock Holdings in Merck & Co., Inc. $MRK

Thrivent Financial for Lutherans grew its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 7.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,379,666 shares of the company’s stock after buying an additional 158,324 shares during the period. Thrivent Financial for Lutherans owned 0.10% of Merck & Co., Inc. worth $199,725,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Darwin Wealth Management LLC increased its position in shares of Merck & Co., Inc. by 237.4% in the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock worth $26,000 after acquiring an additional 216 shares in the last quarter. Kilter Group LLC acquired a new stake in Merck & Co., Inc. in the 2nd quarter valued at $27,000. Bare Financial Services Inc raised its position in Merck & Co., Inc. by 51.9% in the second quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock valued at $29,000 after purchasing an additional 125 shares during the period. Barnes Dennig Private Wealth Management LLC lifted its stake in shares of Merck & Co., Inc. by 302.3% during the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after purchasing an additional 266 shares in the last quarter. Finally, Evolution Wealth Management Inc. acquired a new position in shares of Merck & Co., Inc. during the second quarter worth about $31,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Price Performance

MRK opened at $110.24 on Friday. The company has a market capitalization of $273.62 billion, a P/E ratio of 14.56, a PEG ratio of 1.52 and a beta of 0.29. The company has a 50-day moving average of $105.20 and a 200-day moving average of $91.94. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.44 and a current ratio of 1.66. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $112.90.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.94 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.08 by ($0.14). Merck & Co., Inc. had a net margin of 29.63% and a return on equity of 44.54%. Equities analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is 44.91%.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Zacks highlights strong Keytruda demand and new product launches as key upside drivers into Q4 results, supporting longer?term revenue growth and helping sentiment today. Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings
• Positive Sentiment: Insider/“smart money” activity: Chirfi Guindo bought roughly $1.06M of MRK stock — a buy by an institutional insider can signal confidence and attract momentum buyers. Smart Money Move: Chirfi Guindo Grabs $1.06M Worth Of Merck & Co Stock
• Positive Sentiment: Zacks’ market recap notes MRK outperformed while the broader market dipped, indicating relative strength and sector?specific buying interest. Why the Market Dipped But Merck (MRK) Gained Today
• Neutral Sentiment: Analyst notes and sector coverage (Globe and Mail) provide mixed, mostly informational views on Merck alongside peers—useful for context but not a clear directional trigger. Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Waters (WAT)
• Neutral Sentiment: Additional analyst commentary comparing MRK with UnitedHealth provides sector perspective but no new catalyst. Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and UnitedHealth (UNH)
• Neutral Sentiment: Zacks’ primer on Wall Street estimates and key metrics ahead of Q4 is a useful reference for modeling MRK’s upcoming quarter but doesn’t itself move the needle. Curious about Merck (MRK) Q4 Performance? Explore Wall Street Estimates for Key Metrics
• Neutral Sentiment: Zacks notes MRK is a trending stock on its platform—higher retail/institutional attention increases liquidity and volatility risk but is not a directional catalyst by itself. Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: Zacks warns that declining analyst estimates and rising M&A?related costs could depress near?term results and investor sentiment—key risk ahead of earnings. Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings
• Negative Sentiment: Brokerage consensus is an average “Hold” rating, indicating limited near?term upgrade potential and less bullish analyst conviction. Merck & Co., Inc. (NYSE:MRK) Given Average Rating of “Hold” by Brokerages

Wall Street Analyst Weigh In

Several research firms recently commented on MRK. Weiss Ratings reissued a “hold (c)” rating on shares of Merck & Co., Inc. in a research report on Monday, December 29th. BMO Capital Markets upgraded shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $82.00 to $130.00 in a research note on Thursday, December 18th. UBS Group upped their target price on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Wolfe Research raised shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price target for the company in a report on Thursday, January 8th. Finally, Wells Fargo & Company raised shares of Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $90.00 to $125.00 in a research report on Monday, November 24th. Eight analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $114.53.

Insider Activity

In other news, EVP David Michael Williams sold 8,614 shares of Merck & Co., Inc. stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $83.59, for a total value of $720,044.26. Following the completion of the transaction, the executive vice president directly owned 24,578 shares of the company’s stock, valued at approximately $2,054,475.02. The trade was a 25.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.13% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.